Interleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Prins, Marloes ^a   Eriksson, Charlotta ^a,b   Wierinckx, Anne ^a   Bol, John G J M ^a   Binnekade, Rob ^a   Tilders, Fred J H ^a   Van Dam, Anne Marie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MESSENGER RNA;

ANIMAL; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE EXPRESSION REGULATION; GENETICS; GRAY MATTER; MALE; METABOLISM; MULTIPLE SCLEROSIS; PATHOLOGY; PROTEIN TRANSPORT; RAT; RECURRENT DISEASE; WHITE MATTER;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION; GRAY MATTER; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MULTIPLE SCLEROSIS; PROTEIN TRANSPORT; RATS; RECURRENCE; RNA, MESSENGER; WHITE MATTER;

EID: 84893482404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083835     Document Type: Article

References (123)

1. Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. New England Journal of Medicine 372: 1502-1517.
2. Lassmann H, Brück W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathology 17: 210-218. (Pubitemid 46466140)
3. Lassmann H (2011) Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathology and applied neurobiology 37: 698-710.
4. Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH, et al. (2010) Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Multiple Sclerosis 16: 406-411.
5. Barkhof F (2002) The clinico-radiological paradox in multiple sclerosis revisited. Current opinion in neurology 15: 239-245.
6. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, et al. (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128: 2705-2712. (Pubitemid 41552953)
7. Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ (2003) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. Journal of Neuropathology and Experimental Neurology 62: 723-732.
8. Gilmore CP, Donaldson I, Bö L, Owens T, Lowe J, et al. (2009) Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. Journal of Neurology, Neurosurgery, and Psychiatry 80: 182-187.
9. Geurts JJ, Bo L, Roosendaal SD, Hazes T, Daniels R, et al. (2007) Extensive hippocampal demyelination in multiple sclerosis. Journal of Neuropathology and Experimental Neurology.
10. Bagnato F, Butman JA, Gupta S, Calabrese M, Pezawas L, et al. (2006) In Vivo Detection of Cortical Plaques by MR. American Journal of Neuroradiology 27: 2161-2167.
11. Calabrese M, Rocca MA, Atzori M, Mattisi I, Bernardi V, et al. (2009) Cortical lesions in primary progressive multiple sclerosis A 2-year longitudinal MR study. Neurology 72: 1330-1336.
12. Filippi M, Preziosa P, Pagani E, Copetti M, Mesaros S, et al. (2012) Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis. Multiple Sclerosis Journal 0: 1-9.
13. Sethi V, Yousry TA, Muhlert N, Ron M, Golay X, et al. (2012) Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. Journal of Neurology, Neurosurgery & Psychiatry 83: 877-882.
14. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, et al. (2007) Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Archives of Neurology 64: 1416.
15. Schulz D, Kopp B, Kunkel A, Faiss JH (2006) Cognition in the early stage of multiple sclerosis. Journal of Neurology 253: 1002-1010. (Pubitemid 44441123)
16. Haase CG, Tinnefeld M, Lienemann M, Ganz RE, Faustmann PM (2003) Depression and cognitive impairment in disability-free early multiple sclerosis. Behavioural Neurology 14: 39-45. (Pubitemid 36541505)
17. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Annals of Neurology 50: 389-400. (Pubitemid 32848742)
18. Bø L (2009) The histopathology of grey matter demyelination in multiple sclerosis. Acta Neurologica Scandinavica 120: 51-57.
19. Kooi E-J, Strijbis EMM, van der Valk P, Geurts JJG (2012) Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathologic implications. Neurology 79: 1369-1376.
20. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, et al. (2011) Inflammatory cortical demyelination in early multiple sclerosis. New England Journal of Medicine 365: 2188-2197.
21. Zhao B, Schwartz JP (1998) Mini-Review Involvement of Cytokines in Normal CNS Development and Neurological Diseases: Recent Progress and Perspectives. Journal of Neuroscience Research 16: 7-16. (Pubitemid 28158821)
22. Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nature Reviews Immunology 10: 89-102.
23. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annual Review of Immunology 27: 519-550.
24. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nature Reviews Immunology 5: 629-640. (Pubitemid 41113194)
25. Vitkovic L, Bockaert J, Jacque C (2000) "Inflammatory" cytokines: neuromodulators in normal brain? Journal of Neurochemistry 74: 457-471. (Pubitemid 30053717)
26. Van Dam AM, Brouns M, Louisse S, Berkenbosch F (1992) Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: a pathway for the induction of non-specific symptoms of sickness? Brain research 588: 291-296.
27. Quan N, Whiteside M, Herkenham M (1998) Time course and localization patterns of interleukin-1β messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience 83: 281-293. (Pubitemid 28068057)
28. Palin K, Pousset F, Verrier D, Dantzer R, Kelley K, et al. (2001) Characterization of interleukin-1 receptor antagonist isoform expression in the brain of lipopolysaccharide-treated rats. Neuroscience 103: 161-169. (Pubitemid 32304356)
29. Eriksson C, Nobel S, Winblad B, Schultzberg M (2000) Expression of interleukin 1 alpha and beta, and interleukin 1 receptor antagonist mRNA in the rat central nervous system after peripheral administration of lipopolysaccharides. Cytokine 12: 423-431. (Pubitemid 30449839)
30. Eriksson C, Van Dam A-M, Lucassen P, Bol JGJM, Winblad B, et al. (1999) Immunohistochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 93: 915-930. (Pubitemid 29341639)
31. Brough D, Tyrrell PJ, Allan SM (2011) Regulation of interleukin-1 in acute brain injury. Trends in Pharmacological Sciences 32: 617-622.
32. Takahashi JL, Giuliani F, Power C, Imai Y, Yong VW (2003) Interleukin-1β promotes oligodendrocyte death through glutamate excitotoxicity. Annals of Neurology 53: 588-595. (Pubitemid 36529432)
33. Giulian D, Tapscott MJ (1988) Immunoregulation of Cells within the Central Nervous System. Brain, Behavior, and Immunity 2: 352-358.
34. Feder LS, Laskin DL (1994) Regulation of hepatic endothelial cell and macrophage proliferation and nitric oxide production by GM-CSF, M-CSF, and IL-1 beta following acute endotoxemia. Journal of Leukocyte Biology 55: 507-513. (Pubitemid 24122529)
35. Hong L, Imeri L, Opp MR, Postlethwaite AE, Seyer JM, et al. (1993) Intercellular adhesion molecule-1 expression induced by interleukin (IL)-1 [beta] or an IL-1 [beta] fragment is blocked by an IL-1 receptor antagonist and a soluble IL-1 receptor. Journal of Neuroimmunology 44: 163-170. (Pubitemid 23161394)
36. Perretti M, Solito E, Parente L (1992) Evidence that endogenous interleukin-1 is involved in leukocyte migration in acute experimental inflammation in rats and mice. Inflammation Research 35: 71-78.
37. Constantinescu CS, Farooqi N, O'Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). British Journal of Pharmacology 164: 1079-1106.
38. Brosnan CF, Cannella B, Battistini L, Raine CS (1995) Cytokine localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45: 6-11.
39. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, et al. (2006) Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129: 517-526. (Pubitemid 43164373)
40. Murphy ÁC, Lalor SJ, Lynch MA, Mills KHG (2010) Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain, Behavior, and Immunity 24: 641-651.
41. Bauer J, Berkenbosch F, Van Dam AM, Dijkstra CD (1993) Demonstration of interleukin-1 [beta] in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level. Journal of Neuroimmunology 48: 13-21.
42. Issazadeh S, Lorentzen JC, Mustafa MI, Höjeberg B, Müssener A, et al. (1996) Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. Journal of Neuroimmunology 69: 103-115. (Pubitemid 26305634)
43. Martin D (1995) Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. Journal of Neuroimmunology 61: 241-245.
44. Badovinac V, Mostarica-Stojković M, Dinarello CA, Stosic-Grujicic S (1998) Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. Journal of Neuroimmunology 85: 87-95. (Pubitemid 28255441)
45. Furlan R, Bergami A, Brambilla E, Butti E, De Simoni MG, et al. (2007) HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG35-55-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Therapy 14: 93-98. (Pubitemid 44942870)
46. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, et al. (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathology 8: 681-694. (Pubitemid 28460927)
47. Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, et al. (1995) The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. Journal of Neuroimmunology 63: 17-27.
48. Matthaei I, Polman CH, de Groot CJ, Dijkstra CD, Koetsier JC, et al. (1989) Observer agreement in the assessment of clinical signs in experimental allergic encephalomyelitis. Journal of Neuroimmunology 23: 25-28. (Pubitemid 19125794)
49. Paxinos G, Watson C, Pennisi M, Topple A (1985) Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. Journal of Neuroscience Methods 13: 139-143. (Pubitemid 15008633)
50. Young W (1990) In situ hybridization histochemistry. In: Björklund A, Hökfelt T, Wouterlood FT, Van der Pol AN, editors. Handbook of Chemical Neuroanatomy. pp. 481-512.
51. Schotanus K, Holtkamp G, Meloen R (1995) Domains of rat interleukin 1 beta involved in type I receptor binding. Endocrinology 136: 332-339.
52. Van Dam AM, Poole S, Schultzberg M, Zavala F, Tilders FJH (1995) Effects of Peripheral Administration of LPS on the Expression of Immunoreactive Interleukin-1α, β, and Receptor Antagonist in Rat Brain. Annals of the New York Academy of Sciences 840: 128-138. (Pubitemid 28302044)
53. Dijkstra CD, Döpp EA, Joling P, Kraal G (1985) The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54: 589-599. (Pubitemid 15132717)
54. Wierinckx A, Brevé J, Mercier D, Schultzberg M, Drukarch B, et al. (2005) Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. Journal of Neuroimmunology 166: 132-143. (Pubitemid 41074663)
55. Storch MK, Bauer J, Linington C, Olsson T, Weissert R, et al. (2006) Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatibility complex (MHC) haplotype-related. Journal of Neuropathology and Experimental Neurology 65: 1137-1142. (Pubitemid 44885938)
56. McGuinness MC, Powers JM, Bias WB, Schmeckpeper BJ, Segal AH, et al. (1997) Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. Journal of Neuroimmunology 75: 174-182. (Pubitemid 27170317)
57. Laman JD, van Meurs M, Schellekens MM, de Boer M, Melchers B, et al. (1998) Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). Journal of Neuroimmunology 86: 30-45. (Pubitemid 28293947)
58. Murugesan N, Paul D, Lemire Y, Shrestha B, Ge S, et al. (2012) Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus. Fluids and Barriers of the CNS 9: 15.
59. Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, et al. (2009) The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. Journal of Neuroimmunology 207: 101-106.
60. Kleine TO, Zwerenz P, Graser C, Zöfel P (2003) Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-α, IL-1β, IL-6, IL-8. Brain Research Bulletin 61: 327-346. (Pubitemid 36952479)
61. Dragunow M (2013) Meningeal and choroid plexus cells-novel drug targets for CNS disorders. Brain Research 1501: 32-55.
62. Nisticò R, Mango D, Mandolesi G, Piccinin S, Berretta N, et al. (2013) Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLOS ONE 8: e54666. doi:10.1371/journal.pone.0054666.
63. Batoulis H, Uhl M, Addicks K, Lehmann PV, Kuerten S (2012) The magnitude of the Antigen-Specific T cell response is separated from the severity of spinal cord histopathology in remitting-relapsing experimental autoimmune encephalomyelitis. Glia 60: 794-805.
64. Li Q, Powell N, Zhang H, Belevych N, Ching S, et al. (2011) Endothelial IL-1R1 is a critical mediator of EAE pathogenesis. Brain, Behavior, and Immunity 25: 160-167.
65. Van Dam A-M, De Vries HE, Kuiper J, Zijlstra FJ, De Boer AG, et al. (1996) Interleukin-1 receptors on rat brain endothelial cells: a role in neuroimmune interaction? FASEB Journal 10: 351-356. (Pubitemid 26079956)
66. Graeber MB, Streit WJ (2010) Microglia: biology and pathology. Acta Neuropathologica 119: 89-105.
67. Li H, Cuzner ML, Newcombe J (1996) Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathology and Applied Neurobiology 22: 207-215. (Pubitemid 26177449)
68. Gay FW, Drye TJ, Dick GW, Esiri MM (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 120: 1461-1483.
69. Ferrari CC, Depino AM, Prada F, Muraro N, Campbell S, et al. (2004) Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. The American Journal of Pathology 165: 1827-1837. (Pubitemid 39435180)
70. Jana M, Pahan K (2005) Redox regulation of cytokine-mediated inhibition of myelin gene expression in human primary oligodendrocytes. Free radical biology & medicine 39: 823-831. (Pubitemid 41139895)
71. Thornton P, Pinteaux E, Gibson RM, Allan SM, Rothwell NJ (2006) Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. Journal of Neurochemistry 98: 258-266. (Pubitemid 43882950)
72. Li Y, Liu L, Barger SW, Griffin WST (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. The Journal of Neuroscience 23: 1605-1611. (Pubitemid 36314715)
73. Rossi S, Furlan R, De Chiara V, Motta C, Studer V, et al. (2012) Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Annals of Neurology 71: 76-83.
74. Moreno B, Jukes J-PP, Vergara-Irigaray N, Errea O, Villoslada P, et al. (2011) Systemic inflammation induces axon injury during brain inflammation. Annals of Neurology 70: 932-942.
75. Cai Z, Lin S, Pang Y, Rhodes PG (2004) Brain injury induced by intracerebral injection of interleukin-1beta and tumor necrosis factor-alpha in the neonatal rat. Pediatric Research 56: 377-384. (Pubitemid 39128822)
76. Fan L-W, Mitchell HJ, Tien L-T, Rhodes PG, Cai Z (2009) Interleukin-1beta-induced brain injury in the neonatal rat can be ameliorated by alpha-phenyl-n-tert-butyl-nitrone. Experimental Neurology 220: 143-153.
77. Fan LW, Tien LT, Zheng B, Pang Y, Rhodes PG, et al. (2010) Interleukin-1β-induced brain injury and neurobehavioral dysfunctions in juvenile rats can be attenuated by α-phenyl-n-tert-butyl-nitrone. Neuroscience 168: 240-252.
78. White S, Barnes C (1975) Spinal and spino-bulbo-spinal reflexes in rats with experimental allergic encephalomyelitis. Brain Research 84: 123-128.
79. Sloane E, Ledeboer A, Seibert W, Coats B, van Strien M, et al. (2009) Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain, Behavior, and Immunity 23: 92-100.
80. Olechowski CJ, Truong JJ, Kerr BJ (2009) Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 141: 156-164.
81. Thibault K, Calvino B, Pezet S (2011) Characterisation of sensory abnormalities observed in an animal model of multiple sclerosis: a behavioural and pharmacological study. European Journal of Pain 15: 231.e1-16. Available: http://www.ncbi.nlm.nih.gov/pubmed/20829083. Accessed 2013 Apr 2.
82. Hobom M, Storch MK, Weissert R, Maier K, Radhakrishnan A, et al. (2004) Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathology 14: 148-157. (Pubitemid 38656386)
83. Quinn T, Dutt M, Shindler K (2011) Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis. Frontiers in Neurology 2: 50.
84. Dutt M, Tabuena P, Ventura E, Rostami A, Shindler KS (2010) Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis. Investigative Ophthalmology & Visual Science 51: 1439-1445.
85. Shindler K, Ventura E, Rex T (2007) SIRT1 activation confers neuroprotection in experimental optic neuritis. Investigative Ophthalmology & Visual Science 48: 3602-3609. (Pubitemid 351261095)
86. McDonald WI, Barnes D (1992) The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. Journal of Neurology, Neurosurgery, and Psychiatry 55: 747-752.
87. Balcer LJ (2006) Optic Neuritis. The New England Journal of Medicine 354: 1273-1280.
88. Cruccu G, Biasiotta A, Di Rezze S, Fiorelli M, Galeotti F, et al. (2009) Trigeminal neuralgia and pain related to multiple sclerosis. Pain 143: 186-191.
89. Coelho A, Ceranic B, Prasher D, Miller DH, Luxon ML (2007) Auditory efferent function is affected in multiple sclerosis. Ear and Hearing 28: 593-604. (Pubitemid 47360994)
90. Prosperini L, Kouleridou A, Petsas N, Leonardi L, Tona F, et al. (2011) The relationship between infratentorial lesions, balance deficit and accidental falls in multiple sclerosis. Journal of the Neurological Sciences 304: 55-60.
91. Papadopoulos A, Gatzonis S, Gouliamos A, Trakadas S, Kalovidouris A, et al. (1994) Correlation between spinal cord MRI and clinical features in patients with demyelinating disease. Neuroradiology 36: 130-133. (Pubitemid 24040263)
92. Zackowski KM, Smith SA, Reich DS, Gordon-Lipkin E, Chodkowski BA, et al. (2009) Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 132: 1200-1209.
93. Kalkers NF, Strijers RLM, Jasperse MMS, Neacsu V, Geurts JJG, et al. (2007) Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clinical Neurophysiology 118: 1332-1340. (Pubitemid 46727097)
94. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Annals of Neurology 48: 893-901.
95. De Groot V, Beckerman H, Uitdehaag BM, Hintzen RQ, Minneboo A, et al. (2009) Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis. Archives of Physical Medicine and Rehabilitation 90: 1478-1488.
96. Pollak Y, Orion E, Goshen I, Ovadia H, Yirmiya R (2002) Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of "depression due to multiple sclerosis". Brain, Behavior, and Immunity 16: 533-543. (Pubitemid 35333733)
97. Musgrave T, Benson C, Wong G, Browne I, Tenorio G, et al. (2011) The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain, Behavior, and Immunity 25: 1677-1688.
98. D'Intino G, Paradisi M, Fernandez M, Giuliani A, Aloe L, et al. (2005) Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proceedings of the National Academy of Sciences of the United States of America 102: 3070-3075. (Pubitemid 40299917)
99. Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR (2010) Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Laboratory Investigation 0: 1-13.
100. Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. The Lancet Neurology 7: 1139-1151.
101. Rao S, Leo G, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41: 685-691.
102. Winocur G (1985) The hippocampus and thalamus: their roles in short- and long-term memory and the effects of interference. Behavioural Brain Research 16: 135-152.
103. Lecourtier L, Kelly PH (2007) A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. Neuroscience and Biobehavioral Reviews 31: 658-672. (Pubitemid 46680450)
104. Rimvall K, Keller F, Waser PG (1985) Development of cholinergic projections in organotypic cultures of rat septum, hippocampus and cerebellum. Brain Research 351: 267-278. (Pubitemid 15085401)
105. Benedict RHB, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R (2009) Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology, Neurosurgery, and Psychiatry 80: 201-206.
106. Kooi E-J, Prins M, Bajic N, Beliën J AM, Gerritsen WH, et al. (2011) Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathologica 122: 313-322.
107. Lauterborn JC, Isackson PJ, Montalvo R, Gall CM (1993) In situ hybridization localization of choline acetyltransferase mRNA in adult rat brain and spinal cord. Molecular Brain Research 17: 59-69.
108. Tago H, McGeer PL, McGeer EG, Akiyama H, Hersh LB (1989) Distribution of choline acetyltransferase immunopositive structures in the rat brainstem. Brain Research 495: 271-297. (Pubitemid 19213564)
109. Rada P, Mark GP, Vitek MP, Mangano RM, Blume a J, et al. (1991) Interleukin-1 beta decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Research 550: 287-290.
110. Taepavarapruk P, Song C (2010) Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. Journal of Neurochemistry 112: 1054-1064.
111. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, et al. (2002) β-Amyloid-Induced Inflammation and Cholinergic Hypofunction in the Rat Brain in Vivo: Involvement of the p38MAPK Pathway. Neurobiology of Disease 11: 257-274. (Pubitemid 36135690)
112. Garcia JH, Liu KF, Relton JK (1995) Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. The American Journal of Pathology 147: 1477.
113. Vogt C, Hailer NP, Ghadban C, Korf HW, Dehghani F (2008) Successful inhibition of excitotoxic neuronal damage and microglial activation after delayed application of interleukin-1 receptor antagonist. Journal of Neuroscience Research 86: 3314-3321.
114. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA (2009) Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. British Journal of Pharmacology 140: 471-476.
115. Palin K, Verrier D, Tridon V, Hurst J, Perry VH, et al. (2004) Influence of the course of brain inflammation on the endogenous IL-1beta/IL-1Ra balance in the model of brain delayed-type hypersensitivity response to bacillus Calmette-Guerin in Lewis rats. Journal of Neuroimmunology 149: 22-30. (Pubitemid 38352854)
116. Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunology Today 12: 404-410.
117. Granowitz E, Clark B, Vannier E, Callahan M, Dinarello C (1992) Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79: 2356-2363.
118. Arend WP, Welgus HG, Thompson RC, Eisenberg SP (1990) Biological Properties of Recombinant Human Monocyte-derived Interleukin 1 Receptor Antagonist. Journal of Clin Invest 85: 1694-1697. (Pubitemid 20176469)
119. Loddick SA, Rothwell NJ (1996) Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. Journal of Cerebral Blood Flow and Metabolism 16: 932-940. (Pubitemid 26292060)
120. Nicoletti F, Patti F, DiMarco R, Zaccone P, Nicoletti A, et al. (1996) Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 8: 395-400.
121. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, et al. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 106: 4355-4359.
122. Comabella M, Julià E, Tintoré M, Brieva L, Téllez N, et al. (2008) Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. Journal of Neurology 255: 1136-1141.
123. Liu JS, Amaral TD, Brosnan CF, Lee SC (1998) IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. Journal of Immunology 161: 1989-1996. (Pubitemid 28387624)